Wave Life Sciences Prices $150 Million Public Offering of Ordinary Shares
CAMBRIDGE, Mass., Jan. 24, 2019 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a genetic medicines company focused on […]
Arch Biopartners Arranges Convertible Note Financing
TORONTO, Jan. 24, 2019 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), […]
RGS Energy to Exhibit POWERHOUSE™ Solar Shingles at The NAHB International Builders' Show® on February 19-21, 2019
DENVER, Jan. 24, 2019 (GLOBE NEWSWIRE) — RGS Energy (NASDAQ: RGSE), the exclusive worldwide manufacturer of the visually stunning POWERHOUSE™ […]
Attis Announces R&D Partnership with Iowa State University for Lignin-Based Carbon Fiber
Partnership to Advance Carbon Fiber Research for Use in Major Industries MILTON, GA, Jan. 24, 2019 (GLOBE NEWSWIRE) — via […]
Finjan Mobile Achieves More Than a Million Downloads with its InvinciBull VPN
Enhanced, “Always-on” VPN Spearheads Rapid Adoption EAST PALO ALTO, Calif., Jan. 24, 2019 (GLOBE NEWSWIRE) — Finjan Holdings, Inc. (NASDAQ: […]
CHF Solutions Sponsors Breakfast Symposium on Ultrafiltration Featuring Renowned Cardiologist Daniel Beckles, M.D., Ph.D., at Society of Thoracic Surgeons 55th Annual Meeting
EDEN PRAIRIE, Minn., Jan. 24, 2019 (GLOBE NEWSWIRE) — CHF Solutions (Nasdaq: CHFS), today announced it will be sponsoring a […]
Adial Pharmaceuticals Receives $1.2 Million in Proceeds Through the Exercise of Warrants
Enhances Balance Sheet; Funds to be Utilized for Phase 3 Clinical Trial of AD04 CHARLOTTESVILLE, Va., Jan. 24, 2019 (GLOBE […]
PCSB Financial Corporation Announces Second Fiscal Quarter Results and Declares Quarterly Cash Dividend
YORKTOWN HEIGHTS, N.Y., Jan. 24, 2019 (GLOBE NEWSWIRE) — PCSB Financial Corporation (the “Company”) (NASDAQ: PCSB), parent of PCSB Bank […]
Teligent, Inc. Announces FDA Approval of Clobetasol Propionate Ointment USP, 0.05%
BUENA, N.J., Jan. 24, 2019 (GLOBE NEWSWIRE) — Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today […]
ChemoCentryx Announces Withdrawal of Phase II-Based Conditional Marketing Authorization (CMA) Application for ANCA-Associated Vasculitis in Europe; Phase III ADVOCATE Trial Data Release Planned for Q4 2019
— Companies plan to file for full marketing approval to EMA and FDA in 2020 — MOUNTAIN VIEW, Calif. and […]
